Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Bayer is improving people’s quality of life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of high-quality food, feed and plant-based raw materials.
[IMG]
An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.
We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.
Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.
We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
http://ift.tt/2kFkktb
Latest Report
Core earnings per share
€1.73 (+2.4%)
Group sales
€11.3 billion (+3.5%)
http://ift.tt/2kFgNHr
Financial ratios
http://ift.tt/2kFbsUC
Column 1 Column 2 Column 3
P/E ratio (Price / EPS) 18,3x 16,2x
Capitalization / Revenue 1,87x 1,80x
EV / Revenue 2,20x 2,04x
EV / EBITDA 9,26x 8,49x
Yield (DPS / Price) 2,53% 2,71%
Price to book (Price / BVPS) 3,27x 2,94x
Column 1 Column 2 Column 3
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 18,6% 19,7%
operating Leverage (Delta EBIT / Delta Sales) - 2,40x
Net Margin (Net Profit / Revenue) 10,2% 11,2%
ROA (Net Profit / Asset) 7,65% 8,64%
ROE (Net Profit / Equities) 22,1% 21,5%
Rate of Dividend 46,3% 44,0%
Column 1 Column 2 Column 3
Balance Sheet Analysis 2016e 2017e
CAPEX / CA 5,53% 5,31%
Cash Flow / Sales 17,8% 17,0%
Capital Intensity (Assets / Sales) 1,33x 1,30x
Financial Leverage (Net Debt / EBITDA) 1,37x
imagenes gratis
[IMG]
An analysis by well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.
We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.
Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company’s earning power.
We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
http://ift.tt/2kFkktb
Latest Report
Core earnings per share
€1.73 (+2.4%)
Group sales
€11.3 billion (+3.5%)
http://ift.tt/2kFgNHr
Financial ratios
http://ift.tt/2kFbsUC
Column 1 Column 2 Column 3
P/E ratio (Price / EPS) 18,3x 16,2x
Capitalization / Revenue 1,87x 1,80x
EV / Revenue 2,20x 2,04x
EV / EBITDA 9,26x 8,49x
Yield (DPS / Price) 2,53% 2,71%
Price to book (Price / BVPS) 3,27x 2,94x
Column 1 Column 2 Column 3
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 18,6% 19,7%
operating Leverage (Delta EBIT / Delta Sales) - 2,40x
Net Margin (Net Profit / Revenue) 10,2% 11,2%
ROA (Net Profit / Asset) 7,65% 8,64%
ROE (Net Profit / Equities) 22,1% 21,5%
Rate of Dividend 46,3% 44,0%
Column 1 Column 2 Column 3
Balance Sheet Analysis 2016e 2017e
CAPEX / CA 5,53% 5,31%
Cash Flow / Sales 17,8% 17,0%
Capital Intensity (Assets / Sales) 1,33x 1,30x
Financial Leverage (Net Debt / EBITDA) 1,37x
Bayer AG, a great german company
Aucun commentaire:
Enregistrer un commentaire